Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Chan Cheah, MBBS
Conference Coverage
Epcoritamab Plus R-Mini-CHOP Demonstrates Durable Efficacy and Manageable Safety for Elderly Patients With DLBCL: 2-Year Results From EPCORE NHL-2
12/23/2025
Chan Cheah, MBBS
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naĂŻve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP achieved high and durable response rates with manageable toxicity among elderly, treatment-naĂŻve patients with DLBCL, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Epcoritamab plus R-mini-CHOP...
12/23/2025
Oncology
Krish Patel, MD
Conference Coverage
Quality Improvement Project Identifies Knowledge Gaps and Barriers to Bispecific Antibody Use in Community Oncology Practices
12/17/2025
Krish Patel, MD
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting & Exposition, Krish Patel, MD, shared insights into the development of a quality improvement initiative aimed to identify barriers of bispecific antibody use in community oncology practices.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology

News

News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Polatuzumab-Based Therapy Improves Survival for Patients With R/R DLBCL Ineligible for Transplant
10/28/2025
Emily Estrada
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional...
10/28/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

Interactive Features

Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
Quiz
Polatuzumab-Based Regimens for R/R DLBCL
10/28/2025
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to patients with R/R DLBCL treated with traditional salvage therapies, patients treated with polatuzumab vedotin and zanubrutinib combined with either rituximab or obinutuzumab demonstrated inferior clinical outcomes...
True or False: Compared to...
10/28/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Efficacy and Safety of Tazemetostat for R/R DLBCL and FL
08/25/2025
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results from a meta-analysis evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL, the EZH2 inhibitor demonstrated promise as a viable treatment option, demonstrating meaningful...
True or False: Based on results...
08/25/2025
Oncology
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
Safusidenib Erbumine for IDH1-Mutated Glioma
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naĂŻve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naĂŻve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
Quiz
ISL1 as a Predictive Biomarker for Lurbinectedin Efficacy in Small Cell Lung Cancer
02/05/2026
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging...
02/05/2026
Oncology
Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology

Recent News

News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Odronextamab Plus CHOP Demonstrates High Response Rates and Manageable Safety for Previously Untreated DLBCL: First Results From OLYMPIA-3 Trial
12/03/2025
Emily Estrada
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP chemotherapy achieved high response rates and manageable toxicity for previously untreated DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Odronextamab plus CHOP...
12/03/2025
Oncology
Conference Coverage
Epcoritamab Monotherapy Demonstrates High Response Rates and Durable MRD Negativity in Elderly, Chemotherapy-Ineligible 1L DLBCL Patients: Interim Results from EPCORE DLBCL-3
12/03/2025
Emily Estrada
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous epcoritamab monotherapy demonstrated promising efficacy, early and sustained MRD negativity, and manageable safety among patients with DLBCL, according to data to be presented at the 2025 ASH Annual Meeting.
Fixed-duration subcutaneous...
12/03/2025
Oncology
Conference Coverage
Zanubrutinib Plus R-CHOP Therapy Shows Promising Efficacy, Acceptable Safety Among Patients With DLBCL Harboring Specific Gene Subtypes
12/02/2025
Emily Estrada
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy demonstrated encouraging anti-tumor activity and acceptable tolerability among patients with diffuse large B-cell lymphoma with certain genetic alterations, according to data presented at the 2025 ASH Annual...
Zanubrutinib and R-CHOP therapy...
12/02/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Shows Efficacy and Safety Among Elderly, Chemotherapy-Ineligible Patients With DLBCL: MorningSun Trial
12/02/2025
Emily Estrada
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at the 2025 ASH Annual Meeting, fixed-duration subcutaneous mosunetuzumab monotherapy achieved high response rates with manageable toxicity among elderly/unfit patients with diffuse large B-cell lymphoma.
According to data presented at...
12/02/2025
Oncology
News
Nivolumab Plus R-CHOP Shows Promising Efficacy and Tolerability for Newly Diagnosed DLBCL
12/01/2025
Emily Estrada
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a phase 1b study, the addition of nivolumab to standard R-CHOP therapy demonstrated promising response rates and a manageable safety profile for patients with newly diagnosed aggressive diffuse large B-cell lymphoma.
According to results from a...
12/01/2025
Oncology
News
Rituximab and Lenalidomide Plus Ibrutinib Therapy Shows Promising Activity, Manageable Toxicity in Real-World Setting for Relapsed/Refractory DLBCL
12/01/2025
Emily Estrada
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab, lenalidomide, and ibrutinib demonstrated promising efficacy and survival outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma in a retrospective real-world analysis.
The combination of rituximab,...
12/01/2025
Oncology
News
Ibrutinib-Based Triple Therapy Yields Durable Responses for Newly Diagnosed Primary CNS DLBCL
10/28/2025
Emily Estrada
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly diagnosed primary central nervous system diffuse large B-cell lymphoma, first-line treatment with ibrutinib, rituximab, and high-dose methotrexate demonstrated promising outcomes and manageable safety.
For patients with newly...
10/28/2025
Oncology
News
Polatuzumab-Based Therapy Improves Survival for Patients With R/R DLBCL Ineligible for Transplant
10/28/2025
Emily Estrada
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional chemotherapy, polatuzumab vedotin combined with rituximab and bendamustine demonstrated superior overall survival among patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for transplant.
Compared with conventional...
10/28/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use